Devyser Diagnostics
Devyser strengthens position in Italy - wins tender for cystic fibrosis
Devyser has been awarded a tender for Devyser’s CFTR fragment analysis products, that are used for screening and confirmation of cystic fibrosis. The tender with the University Hospital in Bologna is valid for a period of three years. Indicative order value is estimated to amount to approximately 2 million SEK annually.
"The tender strengthens our already strong position in the Italian market, and I am very proud of the entire team who made this happen", says CEO Fredrik Alpsten. "National and regional screening programs represent important opportunities for us and securing this tender is another confirmation of the competitiveness of our high quality and simple CFTR genetic analysis solutions."
Devyser’s CFTR fragment analysis products are highly sensitive CE-IVD labelled genotyping tests for detection of sequence variants in cystic fibrosis transmembrane conductance regulator (CFTR) gene. Devyser’s CFTR tests are used in the confirmation of cystic fibrosis and for screening of genetic variants in newborns and adults.
Datum | 2023-12-11, kl 11:30 |
Källa | MFN |
![](https://static.allaaktier.se/ads/hand-waving-2.png)